Gilead Sciences | GILD - DEBITO





DEBITO Cambiamento Data
AbbVie USD 72.86B 5.36B 2026-03
Agios Pharmaceuticals USD 35.74M 4.46M 2026-03
ALKERMES USD 1.58B 1.51B 2026-03
Alnylam Pharmaceuticals USD 1.27B 5.33M 2026-03
Amgen USD 57.32B 2.72B 2026-03
Biogen USD 8.09B 1.53B 2026-06
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Bristol-Myers Squibb USD 46.43B 711M 2026-03
Coherus Biosciences USD 294.92M 1.25M 2025-03
Eli Lilly USD 43.37B 867M 2026-03
Gilead Sciences USD 22.17B 2.76B 2026-03
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Glaxosmithkline GBP 19.06B 1.31B 2026-03
Incyte USD 38.27M 1.16M 2026-06
J&J USD 54.99B 7.05B 2026-03
Merck USD 49.12B 222M 2026-03
Moderna USD 1.3B 7M 2026-03
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novartis USD 49.01B 2.02B 2026-06
Pfizer USD 63.73B 231M 2026-03
PTC Therapeutics USD 286.94M 2.42B 2026-03
Puma Biotechnology USD 89.06M 55.07M 2024-06
Regeneron Pharmaceuticals USD 2.71B 400K 2026-06
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 23.58B 3.56B 2026-06
Sarepta Therapeutics USD 1.04B 3.08M 2026-03
United Therapeutics USD 200M 100M 2025-03
Vertex Pharmaceuticals USD 1.99B 44M 2026-03